Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

2(25.0%)

N/A

1(12.5%)

8Total

Phase 1(5)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06830382Recruiting

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

Role: collaborator

NCT07081555Phase 1Recruiting

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

Role: lead

NCT04795141Phase 2Terminated

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

Role: collaborator

NCT03591887Phase 2Completed

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

Role: lead

NCT03580278Phase 1Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

Role: lead

NCT03655353Not ApplicableUnknown

A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Role: collaborator

NCT03502954Phase 1Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

Role: lead

NCT02690142Phase 1Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035

Role: lead

NCT01858116Phase 1Completed

PET Study of Breast Cancer Patients Using [68Ga]ABY-025

Role: collaborator

All 9 trials loaded